Final Results of Albireo`s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017
(WorldNews Health)

- A4250 reduced serum bile acids and improved pruritus in most patients, exhibited a favorable overall tolerability profile - - Albireo to conduct Phase 3 study in children with progressive familial intrahepatic cholestasis - BOSTON, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that final results from its Phase 2 study of lead product candidate A4250 in children with cholestatic liver disease will be presented at the American Association for the Study of Liver Diseases` (AASLD) The Liver Meeting 2017 in Washington, D.C. A poster presentation of the study...